Browse drugs

…ill be enrolled in the dose-escalation cohorts and administered STC-15 orally thrice weekly (TIW) at 3 escalating dose levels in combi…

…city, with G3/4 events reported in 22% compared with 14% in the nivolumab monotherapy arm. An update presented at the European Society of…

…ed favorable CHS-114 mediated anti-tumor remodeling.Conclusions CHS-114 administration to HNSCC patients demonstrates selective depleti…

…poor. The PERICLES study explored a novel strategy of combining atezolizumab with radiation therapy for patients with advanced PeCa. 65 Howe…

…gimens for rNSCLC were durvalumab, nivolumab, pembrolizumab and toripalimab. The estimated hazard ratio of immunotherapy regimens for the a…

…81 ESCC patients from two phase II trials treated with CRT plus toripalimab, with validation in an independent prospective cohort (n=61). N…

… plus ramucirumab and paclitaxel); and b) first-line (1L) TNBC (HCB101 plus toripalimab and nab-paclitaxel). Primary endpoints were sa…

…g DNV3 (anti-LAG-3), toripalimab (anti-PD-1), and chemotherapy (nab-paclitaxel/cisplatin) in 27 Asian patients with unresectable/metastatic me…

…s (n=7, 47%), nivolumab/ipilimumab (n=3, 20%), atezolizumab and durvalumab (n=2 each, 13%), and cemiplimab and toripalimab (n=1 each, 7%) …